Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Micreos logo — Micreos is a biotech company focused on discovering and deve...

Micreos

Micreos is a biotech company focused on discovering and developing recombinant technology

Founded 2022 Switzerland Baar, Switzerland 21 employees Series Unknown Total: $59.50M Biotechnology, Design +1

General Information

Company Name Micreos
Founded Year 2022
Location Switzerland Baar, Switzerland +3
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology, Design, Health Care
Funding Stage Series Unknown
Social

Get notified when Micreos moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Micreos

Micreos is a platform biotech company founded in 2006, with its headquarters in Switzerland. The company focuses on discovering and developing recombinant proteins for chronic Dermatology and Oncology conditions. Micreos is making strides in clinical-stage pharmaceutical biotech, with a vision to positively impact patient care and address global health care systems' concerns about antimicrobial resistance (AMR). Micreos' unique capability in modular engineering to optimize enzyme therapeutics has led to the development of three endolysin-based investigational antimicrobials. These antimicrobials target the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology, and bloodstream infections. The company's mission is to combat harmful bacteria in an era of antimicrobial resistance. Micreos recently secured a significant €25.00M Venture Round investment on 25 October 2022. Micreos' innovative approach to selectively killing only harmful bacteria while preserving the health-enhancing microbiome sets it apart in the biotechnology and healthcare industries. The company's commitment to developing medicinal solutions and forging partnerships across medicine demonstrates its potential to drive meaningful change in the fight against antimicrobial resistance. Overall, Micreos stands at the forefront of biotech innovation, poised to make a significant impact in improving patient outcomes and global healthcare systems.

Taxonomy: biotech company, recombinant proteins, clinical-stage pharmaceutical, antimicrobial resistance, endolysin-based investigational antimicrobials, dermatology, oncology, antibiotic resistance, enzyme therapeutics, microbiome preservation, FDA-approved products, pharmaceutical development, data-driven healthcare solutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 25 Oct 2022
Venture Round •••••• - 30 Sep 2021
Grant •••••• 1 •••• •••• 12 Nov 2019
Venture Round •••••• - 23 May 2012

Micreos Alternatives & Competitors

Micreos vs
Arrevus
Arrevus

Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.

Grant
Biotechnology, Pharmaceutical
Micreos vs
MEDEA Biopharma
MEDEA Biopharma Germany

Developing new generation of sustainable antibacterial solutions.

Seed
10 employees
Micreos vs
IMMUNETHEP
IMMUNETHEP Portugal

For a safer tomorrow

19 employees

FAQ About Micreos

Micreos is a biotech company focused on discovering and developing recombinant technology
Micreos was founded in 2022.
Micreos is headquartered in Baar, Switzerland.
Micreos operates in the following industries: Biotechnology, Design, Health Care.
Micreos has approximately 21 employees.
Micreos has completed 4 funding rounds, raising a total of $59.50M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Micreos include Arrevus, MEDEA Biopharma, IMMUNETHEP, Shionogi Inc. (U.S.), PolyPid Ltd. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Micreos and Arrevus are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Micreos and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy